source
- Longeveron shares plunge 57% after stem-cell therapy fails in mid-stage heart trialLongeveron announced that its investigational stem cell product, laromestrocel, did not meet its primary endpoint in a Phase 2b study of infants with hypoplastic left heart syndrome (HLHS). The tri…
- Roche commits up to $1 billion to develop bispecific antibodies with DualitasRoche announced a partnership with Dualitas Therapeutics, a California biotech, to advance bispecific antibody programs aimed at immunological and inflammatory diseases. The agreement includes an…